Mologen AG. (3/27/19). "Press Release: Top Pharma Manager Stefan M. Manth, MD, to Become CEO of Mologen AG". Berlin.

	Organisation	Mologen AG
	Group	Mologen (Group)
	Organisation 2	Roche (Group)
	Product	lefitolimod (MGN1703)
	Product 2	drug development
	Person	Baumann, Matthias (Mologen 201705– CMO before Noxxon + Focus Clinical Drug Development + Roche + BM)
	Person 2	Krautscheid, Oliver (Mologen 201603 Supervisory Board Chairman)

- To turn therapeutic value created into commercial success

- Read-out of pivotal phase III trial ahead

Stefan M. Manth, MD, MBA, will take over as the new CEO of MOLOGEN AG (ISIN: DE000A2LQ900, SIN A2L Q90) shortly with effect after the completion of the ongoing capital increase, to lead the Company together with Chief Medical Officer (CMO) Dr Matthias Baumann. Dr Manth is a medical doctor with an MBA from the prestigious European Business School INSEAD in Fontainebleau, France, and brings over 35 years of international pharma- und biotech industry experience with him. He has been following MOLOGEN since its inception some 20 years ago and was a member of the Scientific Advisory Board of the Company since 2011. In 2014 he was elected to the Supervisory Board and has since served as Vice Chairman.

"We are delighted, that Stefan Manth has accepted to move into the CEO position. Together with our CMO, we now have the ideal team to head the organization", says Oliver Krautscheid, Chairman of the Supervisory Board at MOLOGEN AG. The new CEO will also become responsible for Finance and Accounting.

Dr Stefan Manth: "MOLOGEN is a pioneer in immunotherapy. The Company is developing promising new medicines which activate the patients' own immune defense to identify and eliminate malignant cells. MOLOGEN is rapidly approaching a decisive milestone this year with its key asset lefitolimod: the highly anticipated read-out of the primary endpoint of our pivotal phase III clinical trial IMPALA in patients with metastatic colorectal cancer." He will strive to maximize the potential value of this trial as well as value created from the other pipeline projects of the Company.

Two decades of management experience within the Roche Group

Dr Stefan M. Manth spent 20 years of his career in different management positions with increasing responsibility within the Roche Group. He was instrumental in building and expanding the oncology franchise at Roche, Genentech and Chugai, the uncontested leader worldwide in this therapeutic field since then. In 2011, Dr Manth joined the Scientific Advisory Board at MOLOGEN AG and was elected to the Supervisory Board in 2014. His successor as Supervisory Board member will be announced in due course.

MOLOGEN AG

MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.

The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM(R).

The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in extensive-stage small cell lung cancer (ES-SCLC) and the data from the extension phase of the TEACH study in HIV have been published.

In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.

MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.

www.MOLOGEN.com

Kontakt

Claudia Nickolaus
Leiterin Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@MOLOGEN.com

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

Record changed: 2023-06-05